Core Points - Algernon Pharmaceuticals Inc. held its annual and special meeting of shareholders, where a resolution to alter the company's authorized share structure to include an unlimited number of Preferred Shares was approved with over 93% of votes in favor [1] - The Series 1 Preferred Shares will offer a ten percent annual dividend and are convertible into ten Common Shares without payment [2] - The company plans to issue a total of 450,000 Preferred Shares and 450,000 Preferred Warrants related to a recent acquisition, along with 1,268,334 Preferred Shares and 634,167 Preferred Warrants from a private placement [2] - All five nominees for the board of directors were elected with over 95% of votes in favor [3] - The company intends to change its name to Algernon Health Inc. to reflect its focus on Alzheimer's Disease diagnostics and plans to establish specialized neuroimaging clinics across North America [4] Company Overview - Algernon Pharmaceuticals is focused on brain-specific PET scanning services for detecting Alzheimer's disease and other neurological conditions, and is also advancing a psychedelic program for stroke and traumatic brain injury [5] - The company holds a 20% equity position in Seyltx, a U.S.-based drug development company working on a chronic cough drug called Ifenprodil [5]